Journal of the American Medical Association (JAMA) Publishes Pivotal Phase 3 Data for Optune Plus Temozolomide to Treat Newly Diagnosed Glioblastoma

Data show Optune plus standard of care temozolomide extended overall survival and progression-free survival of newly diagnosed glioblastoma patients compared to temozolomide alone ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that data from the pivotal phase 3 clinical trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM) have …

Novocure to Hold Webcast to Discuss JAMA Publication of EF-14 Phase 3 Clinical Trial Data

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a webcast today at 5 p.m. EST to discuss the publication of the EF-14 phase 3 clinical trial results in the Journal of the American Medical Association (JAMA). The EF-14 trial data show that treatment with Optune plus standard of care temozolomide significantly extended both progression-free survival …

New Data on Tumor Treating Fields’ Anti-Mitotic Mechanism of Action Published in Scientific Reports

Tumor Treating Fields disrupt mitotic spindle formation leading to irregular chromosome segregation and mitotic catastrophe in cancer cells ST. HELIER, Jersey–(BUSINESS WIRE)–New preclinical data on Novocure’s (NASDAQ: NVCR) Tumor Treating Fields (TTFields) therapy revealed a more thorough understanding of how the therapy works at a cellular level. As an anti-mitotic treatment, TTFields interfere with cancer …

Retrospective Analysis Shows Optune Safe in Glioblastoma Patients with Implanted Non-Programmable Shunts

Removal of FDA contraindication increases addressable GBM patient population ST. HELIER, Jersey–(BUSINESS WIRE)–A retrospective analysis of Novocure’s (NASDAQ: NVCR) Tumor Treating Fields (TTFields) therapy shows that TTFields therapy is safe in adult glioblastoma patients with implanted non-programmable shunts. The data were presented on Nov. 20 at the 20th Annual Society for Neuro-Oncology Meeting in San …

Preliminary Phase 2 Data Demonstrate Tumor Treating Fields is Safe in Patients with Brain Metastases Originating from Non-Small Cell Lung Cancer

ST. HELIER, Jersey–(BUSINESS WIRE)–Preliminary data from COMET, a phase 2 randomized trial sponsored by Novocure (NASDAQ: NVCR), show that the use of Tumor Treating Fields (TTFields) therapy is safe in the treatment of brain metastases originating from non-small cell lung cancer (NSCLC). The results of a preliminary analysis of the ongoing European study were presented …

New Phase 3 Data show Optune in Combination with Second Line Chemotherapy is Superior to Second Line Chemotherapy Alone in Glioblastoma Patients at First Recurrence

Glioblastoma patients who received Optune in combination with bevacizumab at first recurrence lived significantly longer than patients who received bevacizumab alone ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today new Phase 3 data showing that glioblastoma patients who received TTFields in combination with chemotherapy at first recurrence lived significantly longer than patients who received chemotherapy …

Novocure Announces Webcast to Discuss New EF-14 Clinical Trial Analyses and Tumor Treating Fields Presentations from SNO 2015

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will hold a webcast on Monday, Nov. 23, 2015, beginning at 4:30 p.m. EST to discuss the new EF-14 analyses and Tumor Treating Fields (TTFields) presentations from the 20th Annual Meeting of the …

Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data

Quality of life was maintained throughout treatment with Tumor Treating Fields ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company, announced today that a record number of abstracts focusing on Tumor Treating Fields (TTFields) were accepted and will be presented at the 20th Annual Meeting of the Society for Neuro-Oncology on Nov. 19-22 …

Novocure Reports Third Quarter 2015 Operating and Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today reported operating and financial results for the three and nine months ended September 30, 2015. “The last few months were marked by a number of significant milestones. Most notably, on October 5, we received FDA approval …

NovoCure Limited Announces Closing of Partial Exercise of IPO Over-Allotment Option

ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced the closing today of a partial exercise of the over-allotment option by the underwriters of its previously announced initial public offering in the amount of an additional 376,195 ordinary shares at IPO price. There remain …